Radiation therapy for prostate cancer can cause erectile dysfunction (ED). Intensity Modulated Radiation Therapy (IMRT) can reduce the amount of radiation to surrounding tissues associated with ED. We characterize the incidence of and factors associated with ED in prostate cancer patients after IMRT at the National Naval Medical Center (NNMC). Patients potent by definition of the Sexual Health Inventory for Men (SHIM) before treatment completed the specific erectile questions of the SHIM after IMRT. Statistical analyses were performed to examine the relationships between several factors and ED. Thirty-two of 45 patients with mean age of 68.2 years (50-86 years) completed the SHIM. The median follow-up was 36.8 months (16-63.6 months) as defined by the time from completion of therapy to reassessment with the SHIM. Eight of 32 patients (25%) had no post-treatment ED (SHIM score 22-25), three of 32 (9%) had mild post-treatment ED (SHIM score 17-21), five of 32 (16%) had mild to moderate ED (SHIM score 12-16), five of 32 (16%) had moderate ED (SHIM score 8-11) and 11 of 32 (34%) had severe post-treatment ED (SHIM scoreo8). Posttreatment potency was significantly associated with the pre-treatment SHIM score (P ¼ 0.001) and history of hypertension (P ¼ 0.03). The mean radiation dose to the penile bulb and volume of penile bulb treated were not associated with post-treatment potency (P ¼ 0.38, 0.76, respectively). IMRT maintains potency in the majority of patients. This analysis compares favorably in preserving erectile function to previously reported series using conventional external beam radiation therapy techniques. The dose of radiation received by the penile bulb and volume of penile bulb were not associated with post-treatment ED in this analysis.
Introduction
Excluding non-melanoma skin cancer, prostate cancer is the most common cancer and the third most common cause of cancer deaths among men in the United States. 1 Standard treatment options for patients with this disease include external beam radiation, brachytherapy implantation or radical prostatectomy.
2 With treatment outcomes being comparable between modalities, toxicity and quality of life issues have become increasingly important in patients' treatment decisions. 3 A significant issue in determining quality of life after prostate cancer treatment is that of erectile dysfunction (ED). Rates of ED after radical prostatectomy have been reported in the literature ranging from 29 to 91%. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The rates of ED after conventional radiation therapy range from 40 to 65%, [22] [23] [24] [25] [26] [27] and the rates of ED after brachytherapy range from 16 to 50%. 28 The true etiology of ED after radiation therapy remains controversial. Post-radiation ED has been postulated to involve damage to the proximal penile structures, such as the penile bulb, the neurovascular bundles and the local vascular structures. 29, 30 Attempts have been made to correlate radiation dose delivered to the proximal penile structures with the incidence of ED after radiation therapy with conflicting results. 14, 15, 17, 29, 31, 32 Studies have also found a direct relationship between the size of radiation ports and the incidence of ED. 23 Intensity Modulated Radiation Therapy (IMRT) has emerged as a useful tool in the treatment of prostate cancer. IMRT is a highly conformal treatment delivery technique, which allows the delivery of increased or similar tumor doses with relative sparing of normal tissues compared with conventional techniques. Sethi et al. 18 showed that IMRT allowed a significant reduction in the radiation dose to proximal penile structures such as the penile bulb. With implications that the dose to the penile bulb may be associated with rates of ED after radiation treatment, 15, 30 it is conceivable that the use of IMRT as a treatment modality for prostate cancer may allow for improved preservation of erectile function following radiation therapy. There are currently no analyses in the literature of post-treatment erectile function after IMRT. We sought to characterize the incidence of ED after IMRT for prostate cancer in patients treated at National Naval Medical Center (NNMC).
Materials and methods
Between November 1999 and December 2002, 69 patients with clinically localized prostate cancer were treated with IMRT arcs using binary multileaf collimation. Radiation therapy was planned using the Corvus (Nomos, Cranberry, PA, USA) inverse planning system. Daily localization of the prostate was accomplished using a transabdominal ultrasound system.
Before treatment, patients completed the specific erectile questions of the Sexual Health Inventory for Men (SHIM), a validated self-administered test. 33 Patients were considered potent if they scored X10/25 points in the SHIM. Those patients who were potent before IMRT were asked to complete a second SHIM survey at least 24 months after completing treatment. ED was categorized into five categories of ED severity based on the patient's SHIM score: no ED (22) (23) (24) (25) , mild ED (17-21), mild to moderate (12) (13) (14) (15) (16) , moderate (8) (9) (10) (11) and severe (1-7). Patients without pretreatment SHIM scores, SHIM p10 before initiating therapy, or who received anti-androgen therapy within the last 24 months were excluded from analysis. Follow-up was determined by the time interval from completion of therapy to reassessment with the SHIM.
The radiation dose to the penile bulb was calculated by contouring the structure from computed tomography images at 2 mm intervals and a dose volume histogram was obtained in a blinded manner without knowledge of potency results.
Statistical procedures
Multiple variables (patient-related and dosimetric quantifiers) were analyzed for predicting post-treatment ED using a proportional odds regression model. 34 The proportional odds regression model is a well-established statistical technique for regression analysis when the dependent or outcome variable is an ordinal category. We fit the proportional odds regression models defining the outcome variable as an ordinal scale ranging from 1 to 5 where 5 denotes a SHIM score of 22-25, 4 denotes a SHIM score of 17-21, 3 denotes a SHIM score of 12-16, 2 denotes a SHIM score of 8-11 and 1 denotes a SHIM score o8. The magnitude of the association between patient-related and dosimetric variables and the cumulative probability of the 1-5 ordinal score for ED (defined above) was assessed by estimating log-odds ratios in the proportional odds model. A Pp0.05 was the cutoff for declaring statistical significance.
Results
Fifty-two of 69 patients (75%) were potent before initiation of IMRT, determined as a pre-treatment SHIM score X10. Twenty patients were excluded due to insufficient follow-up, non-compliance or recent antiandrogen therapy. Thirty-two of 52 patients with a mean age of 68.2 years (range 50-86 years) completed the erectile-specific questionnaires with sufficient follow-up. The mean duration of follow-up was 36.8 months (range 16-63.6 months). Eight of 32 patients (25%) had no posttreatment ED (SHIM score [22] [23] [24] [25] , three of 32 (9%) had mild post-treatment ED (SHIM score 17-21), five of 32 (16%) had mild to moderate ED (SHIM score 12-16), five of 32 (16%) had moderate ED (SHIM score 8-11), and 11 of 32 (34%) had severe post-treatment ED (SHIM score o8). The mean radiation dose to the penile bulb was 25 Gy. The average radiation dose to 10% (D10), 25% (D25), 50% (D50) and 75% (D75) of the penile bulb were 42.9, 35.7, 24.1 and 25.0 Gy, respectively. Table 1 shows the univariate relationship between patient and treatment factors and post-treatment ED as measured by estimated log-odds ratios from the proportional odds regression models. The mean radiation dose to the penile bulb was not associated with post-treatment potency (P ¼ 0.38). The D10, D25, D50 and D75 also failed to show a relationship with post-radiation ED (P ¼ 0.97, 0.76, 0.24 and 0.23, respectively). The only variables identified as having a significant relationship with post-treatment ED were the pre-treatment SHIM score (P ¼ 0.001) and a history of hypertension (P ¼ 0.03). A pre-treatment SHIM score X20 was found to have a logodds ratio of À2.39 (P ¼ 0.001) for ED. Stated differently, defining impotence by any choice of cutoff value (i.e., as either p1, 2, 3 or 4 on the 1-5 ordinal scale), the odds of a patient with a pre-treatment SHIM X20 being impotent after treatment is e À2.39 , or 0.09 times that of a patient with a pre-treatment SHIM p20.
Likewise, hypertension was found to have a log-odds ratio of 1.54 (P ¼ 0.03) for post-treatment ED. The odds of a patient with hypertension developing ED after IMRT (defined as either p1, 2, 3 or 4), therefore, is e 1.54 , or 4.7 times that of a patient without hypertension. The analysis is based on using a five category ordinal scale summary of the SHIM score, which is described in the Statistical Procedures. a S.e. of the estimated log-odds ratio. The 95% confidence interval for the log-odds ratios can be estimated by multiplying 1.96 Â (s.e.), for example, 95% confidence interval for the log-odds ratio for pre-treatment SHIM 420 is À2.397 (1.96 Â 0.74), or alternatively, À0.94 to À3.84. b The log-odds ratio for continuous variables corresponds to the change in the log-odds ratio of impotence for a unit change in the variable.
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The remaining patient variables, including anti-androgen therapy, arteriosclerosis, hyperlipidemia and smoking history failed to show a statistically significant relationship with erectile function outcomes after IMRT. The radiation treatment variables of mean penile bulb dose, D10, D25, D50 and D75 were also unrelated to potency outcomes.
Additionally, we fit a multivariate model with both pre-treatment SHIM score and hypertension predicting the ordinal (1-5) outcome of post-treatment ED. Pretreatment SHIM score remained strongly associated with post-treatment ED (log-odds ratio ¼ À2.13, P ¼ 0.01), but hypertension was not significantly related to posttreatment ED after adjusting for pre-treatment SHIM score (log-odds ratio ¼ 0.53, P ¼ 0.50).
Discussion
In an era where treatment outcomes for prostate cancer patients are comparable between radiation therapy and radical prostatectomy, 2 patients' decisions rely heavily on the consideration of treatment toxicity and quality of life issues. One of the major concerns expressed by patients undergoing either treatment is that of sexual potency after treatment. 3 Numerous reports have been published regarding the incidence and impact of, as well as the possible mechanism for, post-radiation ED. IMRT has emerged as a useful tool in the treatment of multiple diseases, including prostate cancer. IMRT has been shown to effectively decrease the relative radiation dose to adjacent structures such as bowel and bladder. Dosimetric studies of IMRT in the treatment of prostate cancer have shown the ability to reduce radiation dose specifically to proximal penile structures such as the penile bulb. 18, [42] [43] [44] Radiation dose to the penile bulb has been the subject of several studies concerning radiation-induced ED. 9, 10, [30] [31] [32] Although the results of these reports are often conflicting, there is at least some evidence to suggest that by minimizing radiation dose to the proximal penile structures, the risk of radiation-induced ED may be significantly decreased. Zelefsky et al. 27 reported a 5-year actuarial risk of post-radiation ED of 60% following three-dimensional conformal beam radiation therapy (3DCRT). The authors identified both radiation dose 475.6 Gy and neoadjuvant hormone therapy as independent predictors of ED after radiation therapy. Fisch et al. 30 also reported a dose-dependent relationship with post-radiation ED. In their report, the authors found that if 70% of the penile bulb exceeded 70 Gy, the likelihood of developing ED increased significantly, whereas at doses less than 40 Gy, the risk was significantly lower. Regarding ED after brachytherapy, Macdonald et al. 45 reported no correlation between penile bulb dose and risk of ED.
Although the definitive etiology of radiation-induced ED remains undetermined, animal studies have suggested that damage to nitric-oxide synthase containing nerves within the bulb of the penis may account for radiation-induced impotence. 46 As mentioned above, there is also evidence of a dose-dependent relationship in the possible link between radiation to the penile bulb and the incidence of ED. 15, 30 Damage to other structures of the proximal penis, such as the corpus cavernosus and the neurovascular bundles, as well as arteriogenic etiologies have also been implicated in radiationinduced ED. 9, 10, 20, 40 Zelefsky and Eid 40 reported on a series of 98 patients with ED after definitive therapy for prostate cancer. Among patients treated with radiation therapy, the authors reported that 63% had an arteriogenic etiology, whereas 32% had venous leak. Among all patients with ED after treatment, 7% were reported as having a neurogenic etiology to their condition.
Based both on evidence that IMRT can effectively reduce the dose of radiation to the structures of the proximal penis and on evidence for increased risk of post-radiation ED with increasing doses to the proximal penile structures, it is conceivable that IMRT could deliver therapeutic doses of radiation therapy to the prostate, while minimizing radiation dose to the penile bulb, thereby potentially reducing the risk of postradiation ED.
Data from our institution show that erectile function and sexual potency are well maintained in men treated with IMRT for prostate cancer. Our patients reported ED ranging from no ED to moderate ED in 66% of patients, whereas 34% reported severe ED. This compares quite favorably to historic data reporting an ED incidence of 40-65% after treatment with convention external beam irradiation or 3DCRT. Furthermore, no association was seen between the mean penile bulb radiation dose and potency outcomes. Only pre-treatment potency and a history of hypertension were significantly associated with changes in potency outcomes. However, after adjusting for pre-treatment potency, a history of hypertension failed to be associated with post-treatment ED.
As standard therapy for prostate cancer moves forward with the use of ever increasing doses of radiation, the importance of minimizing radiation dose to the proximal penile structures will only become more prominent. Further analyses and documentation of ED after external beam radiation therapy with IMRT will be necessary to delineate fully the potential benefits of IMRT therapy, especially in the setting of dose escalation. Our findings, however, suggest that IMRT may afford prostate cancer patients undergoing radiation therapy potency outcomes comparable to, if not superior to, historic data.
